Anhui Sunhere Pharmaceutical Excipients Co Ltd

The company maintains a market price of 12.55 CNY, with a market capitalization of 2.94 billion CNY. Its price-to-earnings ratio is 16.67, and its price-to-book ratio is 2.92, indicating a moderate premium over book value. The enterprise value to EBITDA ratio is 16.42, and the enterprise value to revenue ratio is 3.47, suggesting a relatively high valuation relative to earnings and revenue.

In terms of profitability, the company reports a return on equity of 17.54% and a return on assets of 10.31%, both of which are strong indicators of efficient capital use and asset management. The gross profit margin is 31.74%, and the operating margin is 21.10%, which are both above the industry median for pharmaceutical companies. The net profit margin is 18.72%, reflecting a healthy conversion of revenue into net income.

Geographically and segment-wise, the company's revenue is not disclosed by region or product line in the available data. However, the company operates in the pharmaceutical excipients market, which is a critical component of the broader pharmaceutical industry. The lack of detailed segment data limits the ability to assess geographic or product concentration risk.

Looking at growth, the company's revenue for the latest period is 942.8 million CNY. While no specific growth rate is provided, the company's operating cash flow of 191.99 million CNY and free cash flow of 114.42 million CNY suggest a strong cash-generating ability. The capital expenditure of -40.73 million CNY indicates a reduction in capital spending, which may signal a shift in strategic focus or a response to market conditions.

The company faces a medium liquidity risk, as noted in the risk assessment, and a low dilution risk. However, the key flag of negative net cash after subtracting total debt suggests potential liquidity constraints. The debt-to-equity ratio is 0.32, and the current ratio is 4.14, indicating a strong short-term liquidity position despite the debt burden.

Recent events and disclosures include analyst price targets, with a mean, median, high, and low price target all set at 15.60 CNY. This consensus suggests a positive outlook from analysts, although the company's financials must be monitored for any changes in this sentiment.